Wikidata |

Wikidata

Matches in Wikidata for { <http://www.wikidata.org/entity/Q61647235> ?p ?o ?g. }

Showing items 1 to 100 of ±109 with 100 items per page.

Q61647235 description "2018 թվականի օգոստոսի 11-ին հրատարակված գիտական հոդված" @default.
Q61647235 description "artículu científicu espublizáu n'agostu de 2018" @default.
Q61647235 description "im August 2018 veröffentlichter wissenschaftlicher Artikel" @default.
Q61647235 description "scientific article published on 11 August 2018" @default.
Q61647235 description "wetenschappelijk artikel" @default.
Q61647235 description "наукова стаття, опублікована в листопаді 2018" @default.
Q61647235 name "Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE)" @default.
Q61647235 name "Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE)" @default.
Q61647235 type Item @default.
Q61647235 label "Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE)" @default.
Q61647235 label "Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE)" @default.
Q61647235 prefLabel "Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE)" @default.
Q61647235 prefLabel "Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE)" @default.
Q61647235 P1433 Q61647235-81E7C5BD-F99C-47D3-AC5D-D5DB8129627D @default.
Q61647235 P1476 Q61647235-172ECA79-512D-4DE9-BB9B-ED9A066C3EC0 @default.
Q61647235 P2093 Q61647235-0F7F3422-695D-445A-810D-558854A24AB9 @default.
Q61647235 P2093 Q61647235-4BD9EB26-27E9-4247-ACA9-5DB2D27BAE61 @default.
Q61647235 P2093 Q61647235-9DF87AFD-34CA-4D37-B688-17C28A90BB72 @default.
Q61647235 P2093 Q61647235-B45876B3-EEDC-488C-8760-B081709E0D6B @default.
Q61647235 P2093 Q61647235-D57B8692-B710-4F62-B3DA-22C89D47AF17 @default.
Q61647235 P2093 Q61647235-ED6B59A5-5C6E-4537-A10F-CC690276DA06 @default.
Q61647235 P2093 Q61647235-F60BABE4-E16C-4446-A8EB-3CE1F84C1BCC @default.
Q61647235 P2507 Q61647235-47380565-ED1B-4CE0-B1F2-23183AC5BCF1 @default.
Q61647235 P2860 Q61647235-1C5BC3DE-FA1F-4303-B894-FA525E7274DF @default.
Q61647235 P2860 Q61647235-268ACFA5-5103-44CF-A926-2DA405AB3FD7 @default.
Q61647235 P2860 Q61647235-3700F621-D1EF-4468-8E8B-93C95D3EC587 @default.
Q61647235 P2860 Q61647235-3A79B3A8-809E-4C9C-957F-BB34D3663BDD @default.
Q61647235 P2860 Q61647235-49F28947-B81D-4E36-B49F-67B8963F8C2D @default.
Q61647235 P2860 Q61647235-65FF0547-7AE4-4807-9B20-DE7234C48D0B @default.
Q61647235 P2860 Q61647235-76C1C895-2BD4-49D3-818B-7B725FAD1292 @default.
Q61647235 P2860 Q61647235-7E3193BE-9E91-47A7-81AA-24EA2E3487DB @default.
Q61647235 P2860 Q61647235-83055F19-71E2-41A1-B747-08576525BEF6 @default.
Q61647235 P2860 Q61647235-88E5D11D-0DC1-46EA-8501-3823BE466A03 @default.
Q61647235 P2860 Q61647235-95EB079C-0816-41FF-9402-2C8CC012C6A2 @default.
Q61647235 P2860 Q61647235-964CC182-9BBA-4091-88EF-08434E66FD61 @default.
Q61647235 P2860 Q61647235-96F038C3-506F-4E67-A693-C4EC01D34A23 @default.
Q61647235 P2860 Q61647235-9AD6BB05-0FFC-48D5-99B4-7273C6865959 @default.
Q61647235 P2860 Q61647235-9D379DAA-87B0-4AB4-82C5-35202A2EC75C @default.
Q61647235 P2860 Q61647235-9E751070-9725-4F44-8B0A-49C6576DE6E6 @default.
Q61647235 P2860 Q61647235-B1EC2D36-793E-46B8-9467-A04CC5FBA520 @default.
Q61647235 P2860 Q61647235-B2E90212-224E-4261-903F-79F46E17F462 @default.
Q61647235 P2860 Q61647235-B9295F51-14DD-48B9-85B4-ED0894255667 @default.
Q61647235 P2860 Q61647235-D6DDBB1C-3EF2-43D9-9FAF-01AE93F2B052 @default.
Q61647235 P2860 Q61647235-D8337046-6221-41C4-AEB8-FBA86ADE33C9 @default.
Q61647235 P2860 Q61647235-DD98BDD0-0464-40D4-BAA6-C3A48745252B @default.
Q61647235 P2888 Q61647235-01A94190-A410-4F0F-98D1-46961DB80C7A @default.
Q61647235 P304 Q61647235-36F4A192-DD79-4936-A353-C91317538ECC @default.
Q61647235 P31 Q61647235-B8AD53EF-5EAC-4D96-AE5F-3F086DC00EED @default.
Q61647235 P356 Q61647235-92ABF42E-0B17-45BA-92D4-F1FF6B4BE474 @default.
Q61647235 P407 Q61647235-375126D4-A69A-4DF2-8DAA-E376F77AF7D2 @default.
Q61647235 P433 Q61647235-DAB0CC89-98C5-4FE0-B431-5C57365A6C2E @default.
Q61647235 P478 Q61647235-FC1D6701-A26C-46EF-8398-00E664FFC7E2 @default.
Q61647235 P50 Q61647235-22F8FE24-A98B-4810-9821-9C5D05B6EFB2 @default.
Q61647235 P577 Q61647235-C6C9BF1C-21C1-4DAA-A76E-72A066ED784B @default.
Q61647235 P6179 Q61647235-8C3CFE98-65BE-454A-BA42-079E2AD4C1EE @default.
Q61647235 P698 Q61647235-CC5D3A46-E353-41E6-91B4-CBE3D76CD6E9 @default.
Q61647235 P921 Q61647235-06B39FFF-F799-4085-88AE-951F71DFAAE9 @default.
Q61647235 P921 Q61647235-0F3B0721-6F9B-4720-9C8A-4B92DD66C5BC @default.
Q61647235 P921 Q61647235-91E49B83-6C2C-4E5D-8D2A-C8147F896F26 @default.
Q61647235 P932 Q61647235-BBBE892A-86CC-4348-AAA1-69535C9A5641 @default.
Q61647235 P356 S10096-018-3344-1 @default.
Q61647235 P698 30099637 @default.
Q61647235 P1433 Q15754378 @default.
Q61647235 P1476 "Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE)" @default.
Q61647235 P2093 "Areti Georgopali" @default.
Q61647235 P2093 "Emilio Bouza" @default.
Q61647235 P2093 "Florian Thalhammer" @default.
Q61647235 P2093 "Graham Wetherill" @default.
Q61647235 P2093 "Joop van Oene" @default.
Q61647235 P2093 "Maria J G T Vehreschild" @default.
Q61647235 P2093 "Surabhi Taori" @default.
Q61647235 P2507 Q58579561 @default.
Q61647235 P2860 Q26996462 @default.
Q61647235 P2860 Q34162172 @default.
Q61647235 P2860 Q34285444 @default.
Q61647235 P2860 Q34329633 @default.
Q61647235 P2860 Q36494422 @default.
Q61647235 P2860 Q36499033 @default.
Q61647235 P2860 Q37334099 @default.
Q61647235 P2860 Q37588248 @default.
Q61647235 P2860 Q37723471 @default.
Q61647235 P2860 Q38028945 @default.
Q61647235 P2860 Q38057405 @default.
Q61647235 P2860 Q38151926 @default.
Q61647235 P2860 Q38930594 @default.
Q61647235 P2860 Q40290996 @default.
Q61647235 P2860 Q40397688 @default.
Q61647235 P2860 Q40426045 @default.
Q61647235 P2860 Q40513250 @default.
Q61647235 P2860 Q41553725 @default.
Q61647235 P2860 Q42222510 @default.
Q61647235 P2860 Q43719930 @default.
Q61647235 P2860 Q44310798 @default.
Q61647235 P2860 Q61713430 @default.
Q61647235 P2888 s10096-018-3344-1 @default.
Q61647235 P304 "2097-2106" @default.
Q61647235 P31 Q13442814 @default.
Q61647235 P356 "10.1007/S10096-018-3344-1" @default.
Q61647235 P407 Q1860 @default.
Q61647235 P433 "11" @default.